BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26909589)

  • 21. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
    J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
    He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M
    Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation of BAALC and ERG Gene Expression with Overall Survival in Acute Myeloid Leukemia Cases.
    Rashed RA; Kadry DY; El Taweel M; Abd El Wahab N; Abd El Hameed T
    Asian Pac J Cancer Prev; 2015; 16(17):7875-82. PubMed ID: 26625814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
    Tabata MM; Chase M; Kwong BY; Novoa RA; Fernandez-Pol S
    J Cutan Pathol; 2020 Nov; 47(11):1042-1045. PubMed ID: 32588467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of ERG-antibody in Benign Mimickers of Prostate Cancer.
    Bachurska SY; Staykov DG; Ivanov GP; Belovezhdov VT
    Folia Med (Plovdiv); 2016 Mar; 58(1):48-53. PubMed ID: 27383878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria.
    Kaddu S; Zenahlik P; Beham-Schmid C; Kerl H; Cerroni L
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):966-78. PubMed ID: 10365929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation.
    Dorfman DM; Morgan EA; Pelton A; Unitt C
    Hum Pathol; 2017 Jul; 65():166-174. PubMed ID: 28551327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leukemia cutis as the presenting symptom of acute myeloid leukemia: report of three cases.
    Moyer AB; Rembold J; Lee NE; Johnson G; Gardner JM
    Dermatol Online J; 2018 May; 24(5):. PubMed ID: 30142735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characterization of leukemia cutis presentation.
    Haidari W; Strowd LC
    Cutis; 2019 Dec; 104(6):326-330;E3. PubMed ID: 31939929
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Zaliova M; Potuckova E; Hovorkova L; Musilova A; Winkowska L; Fiser K; Stuchly J; Mejstrikova E; Starkova J; Zuna J; Stary J; Trka J
    Haematologica; 2019 Jul; 104(7):1407-1416. PubMed ID: 30630977
    [No Abstract]   [Full Text] [Related]  

  • 31. Myeloid leukemia cutis in the setting of myelodysplastic syndrome: a crucial dermatological diagnosis.
    Patel LM; Maghari A; Schwartz RA; Kapila R; Morgan AJ; Lambert WC
    Int J Dermatol; 2012 Apr; 51(4):383-8. PubMed ID: 22435424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
    Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm.
    Cronin DM; George TI; Reichard KK; Sundram UN
    Am J Clin Pathol; 2012 Mar; 137(3):367-76. PubMed ID: 22338048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Leukemia cutis: clinical features of 27 mexican patients and a review of the literature].
    Peña-Romero AG; Domínguez-Cherit J; Méndez-Flores S
    Gac Med Mex; 2016; 152(5):439-443. PubMed ID: 27792708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Over expression of brain and acute leukemia, cytoplasmic and ETS-related gene is associated with poor outcome in acute myeloid leukemia.
    Hasan SK; Patkar NV; Rajamanickam D; Gokarn A; Lucena-Araujo AR; Tembhare P; Bagal B; Kadam Amare P; Jain H; Gujral S; Sengar M; Subramanian PG; Khattry N
    Hematol Oncol; 2020 Dec; 38(5):808-816. PubMed ID: 32893896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
    Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ERG expression in multiple myeloma-A potential diagnostic pitfall.
    Knief J; Reddemann K; Gliemroth J; Brede S; Bartscht T; Thorns C
    Pathol Res Pract; 2017 Feb; 213(2):130-132. PubMed ID: 27913051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Significance of ERG and Androgen Receptor Expression in Adenocarcinoma Prostate.
    Husain I; Sagar P; Shukla S; Babu S; Singhai A; Sankhwar SN; Husain N
    Kathmandu Univ Med J (KUMJ); 2018 Oct.-Dec.; 16(64):277-280. PubMed ID: 31729338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy.
    Morais CL; Han JS; Gordetsky J; Nagar MS; Anderson AE; Lee S; Hicks JL; Zhou M; Magi-Galluzzi C; Shah RB; Epstein JI; De Marzo AM; Lotan TL
    Am J Surg Pathol; 2015 Feb; 39(2):169-78. PubMed ID: 25517949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis.
    Weber S; Haferlach T; Haferlach C; Kern W
    Blood Cancer J; 2016 Dec; 6(12):e507. PubMed ID: 27935581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.